mofezolac has been researched along with Cancer of Ovary in 1 studies
mofezolac: Cyclooxygenase 1 inhibitor; structure in first source; RN from Toxlit
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ovarian cancer is among the highest mortality gynecological cancers." | 1.51 | Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection. ( Aleem, AM; Ferorelli, S; Fortuna, CG; Iaselli, MC; Marnett, LJ; Miciaccia, M; Pati, ML; Perrone, MG; Scilimati, A, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scilimati, A | 1 |
| Ferorelli, S | 1 |
| Iaselli, MC | 1 |
| Miciaccia, M | 1 |
| Pati, ML | 1 |
| Fortuna, CG | 1 |
| Aleem, AM | 1 |
| Marnett, LJ | 1 |
| Perrone, MG | 1 |
1 other study available for mofezolac and Cancer of Ovary
| Article | Year |
|---|---|
Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection.
Topics: Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Fem | 2019 |